Intravitreal injections with anti-VEGF biological treatments (anti-angiogenic therapies that target VEGF) are first-line therapy for treating and stabilizing exudative neovascular AMD (nAMD).

Patients with neovascular age-related macular degeneration (nAMD), diabetic retinopathy (DR), diabetic macular edema (DME), and retinal vein occlusion (RVO) often face challenges due to the ...

High-dose aflibercept offers extended dosing intervals for DME and wet AMD, with sustained visual and anatomical improvements. The PULSAR and PHOTON trials showed efficacy in maintaining vision ...

Congressional budget plans could set the stage for hundreds of billions of dollars in federal cuts to Medicaid and the Children’s Health Insurance Program (CHIP), the joint state-federal ...

All patient groups showed a reduction in central retinal thickness (CRT). Notably, eyes with nAMD and fibrosis-associated hyperreflective material (HRM) exhibited a significant decrease in HRM volume ...

Vabysmo is now the most prescribed treatment in AMD in the US. Market shares in the US continue to expand with nAMD now at 33%. That's up 3% DME up 2% and RVO up 3%. This is also true for ex US ...

AI-driven biomarker segmentation enhances monitoring of treatment-resistant nAMD, offering precise and scalable insights into disease progression. Faricimab's dual mechanism may benefit patients ...

“The activity of macular neovascularization in nAMD is commonly indicated by an increase in different optical coherence tomography (OCT) biomarkers such as mean central retinal thickness (CRT) (mean ...

A structured proactive monitoring protocol can detect intraocular inflammation (IOI) early and enable favorable visual outcomes in patients with resistant neovascular age-related macular degeneration ...